Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Wayne Tam"'
Autor:
Stephanie N. Hurwitz, Robert P. Hasserjian, Adam Bagg, Eric D. Hsi, L. Jeffrey Medeiros, Valentina Nardi, Prithviraj Bose, Attilio Orazi, Roberto N. Miranda, Daniel A. Arber, Kathryn Foucar, Guilin Tang, David Wu, Wei Wang, Heesun J. Rogers, Carlos E. Bueso-Ramos, Nicholas J. Short, Wayne Tam, Sa A. Wang, Andrés E. Quesada
Publikováno v:
Modern Pathology. 34:1673-1685
Myeloid/lymphoid neoplasms (M/LN) with 13q12/FLT3 rearrangement have been suggested as candidates for possible inclusion in the World Health Organization classification group of M/LN with eosinophilia (M/LN-eo). We report 12 patients with confirmed F
Autor:
Robert P. Hasserjian, Karen M. Chisholm, Mina L. Xu, Olga K. Weinberg, Daniel Babu, Wayne Tam, Tracy I. George, Bartosz Grzywacz, Adam Bagg, Daniel A. Arber, Jason H. Kurzer, Sa A. Wang, Siddharth Bhattacharya, Wei Wang, Yuri Fedoriw, Kathryn Foucar, Attilio Orazi, Emily F. Mason, Chi Young Ok, Karen A. Moser
Publikováno v:
Modern Pathology. 34:1358-1366
Natural killer (NK) cells are lymphocytes of the native immune system that play a pivotal role in host defense and immune surveillance. While the conceptual view of NK-neoplasms is evolving, little is known about the rare NK lymphoblastic leukemia (N
Autor:
Olga K. Weinberg, Chi Young Ok, Tracy I. George, Sa A. Wang, Adam Bagg, Daniel A. Arber, Heesun J. Rogers, Kevin T. Trowell, Wayne Tam, Kaaren K. Reichard, Kyle Parker, Robert P. Hasserjian, Attilio Orazi, Eric D. Hsi, Carlos E. Bueso-Ramos, Karen A. Moser
Publikováno v:
Modern Pathology. 34:20-31
JAK2, CALR, and MPL are myeloproliferative neoplasm (MPN)-driver mutations, whereas SF3B1 is strongly associated with ring sideroblasts (RS) in myelodysplastic syndrome (MDS). Concomitant mutations of SF3B1 and MPN-driver mutations out of the context
Autor:
Leandro Cerchietti, Jia Ruan, David M. Hyman, Sonali M. Smith, Morton Coleman, Amelyn Rodriguez, Paul J. Christos, Stephen J. Schuster, Bijal D. Shah, John P. Leonard, Wayne Tam, Peter Martin, Maria Nieves Calvo-Vidal, Jakub Svoboda, Richard R. Furman
Publikováno v:
Blood. 132:2016-2025
We report 5-year follow-up of a multicenter phase 2 study of lenalidomide plus rituximab (LR) as initial treatment of mantle cell lymphoma (MCL). The regimen includes induction and maintenance with the LR doublet. Treatment was continuous until progr
Autor:
Lan V. Pham, Govind Bhagat, Xudong Wang, Xiaosheng Fang, Karen Dybkær, Michael Boe Møller, Fredrick B. Hagemeister, Zijun Y. Xu-Monette, Andrés J.M. Ferreri, Miguel A. Piris, Bing Xu, Jooryung Huh, Feng Zhu, Yong Li, April Chiu, J. Han van Krieken, Alexandar Tzankov, Jane N. Winter, Manman Deng, Carlo Visco, Ken H. Young, Benjamin M. Parsons, Hua You, Youli Zu, Maurilio Ponzoni, Phillip Liu, Wayne Tam, Eric D. Hsi
Publikováno v:
Molecular Cancer Research, 19, 249-260
Deng, M, Xu-Monette, Z Y, Pham, L V, Wang, X, Tzankov, A, Fang, X, Zhu, F, Visco, C, Bhagat, G, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Moller, M B, Parsons, B M, Hagemeister, F, van Krieken, J H, Piris, M A, Winter, J N, Li, Y, Xu, B, Liu, P & Young, K H 2021, ' Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents ', Molecular Cancer Research, vol. 19, no. 2, pp. 249-260 . https://doi.org/10.1158/1541-7786.MCR-20-0466
Mol Cancer Res
Molecular Cancer Research, 19, 2, pp. 249-260
Deng, M, Xu-Monette, Z Y, Pham V, L, Wang, X, Tzankov, A, Fang, X, Zhu, F, Visco, C, Bhagat, G, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Moller, M B, Parsons, B M, Hagemeister, F, van Krieken, J H, Piris, M A, Winter, J N, Li, Y, Xu, B, Liu, P & Young, K H 2021, ' Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents ', Molecular Cancer Research, vol. 19, no. 2, pp. 249-260 . https://doi.org/10.1158/1541-7786.MCR-20-0466
Deng, M, Xu-Monette, Z Y, Pham, L V, Wang, X, Tzankov, A, Fang, X, Zhu, F, Visco, C, Bhagat, G, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Moller, M B, Parsons, B M, Hagemeister, F, van Krieken, J H, Piris, M A, Winter, J N, Li, Y, Xu, B, Liu, P & Young, K H 2021, ' Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents ', Molecular Cancer Research, vol. 19, no. 2, pp. 249-260 . https://doi.org/10.1158/1541-7786.MCR-20-0466
Mol Cancer Res
Molecular Cancer Research, 19, 2, pp. 249-260
Deng, M, Xu-Monette, Z Y, Pham V, L, Wang, X, Tzankov, A, Fang, X, Zhu, F, Visco, C, Bhagat, G, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, You, H, Huh, J, Ponzoni, M, Ferreri, A J M, Moller, M B, Parsons, B M, Hagemeister, F, van Krieken, J H, Piris, M A, Winter, J N, Li, Y, Xu, B, Liu, P & Young, K H 2021, ' Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents ', Molecular Cancer Research, vol. 19, no. 2, pp. 249-260 . https://doi.org/10.1158/1541-7786.MCR-20-0466
Diffuse large B-cell lymphoma (DLBCL) is the major type of aggressive B-cell lymphoma. High-grade B-cell lymphoma (HGBCL) with MYC/BCL2 double-hit (DH) represents a distinct entity with dismal prognosis after standard immunochemotherapy in the curren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e0ca1e115531ef15519d5ec6d4a3659
https://doi.org/10.1158/1541-7786.MCR-20-0466
https://doi.org/10.1158/1541-7786.MCR-20-0466
Publikováno v:
Leukemia research. 100
GATA binding protein 1 (GATA1) is a transcription factor essential for effective erythropoiesis and megakaryopoiesis. Two isoforms of GATA1 exist, derived from alternative splicing. "GATA1" is the full length and functionally active protein; "GATA1s"
Publikováno v:
Seminars in diagnostic pathology. 38(2)
Hematopoietic neoplasms involving the spleen are uncommon, but T cell neoplasms involving the spleen are extremely rare. The rarity of splenic involvement by T cell neoplasms has resulted in a limited body of literature describing their splenic chara
Myeloid, mast cell, histiocytic and dendritic cell neoplasms and proliferations involving the spleen
Publikováno v:
Seminars in diagnostic pathology. 38(2)
Splenic involvement and consequent splenomegaly are usually seen as part of systemic involvement by myeloid neoplasms as well as mast cell and histiocytic neoplasms. Primary splenic involvement by these neoplasms is rare. Splenectomy is usually not p
Autor:
David Wilkes, Justin D. Kaner, Jeanne P. De Leon, Sahil Sharma, Gabriela Chiosis, Mayumi Sugita, Koen van Besien, LunBiao Yan, Luke C. Olson, Reyna A. Jimenez-Flores, Jaclyn A. Croyle, Juan Miguel Mosquera, Theresa Y. MacDonald, Swathi Merugu, David S. Rickman, Mark A. Rubin, Jenny Xiang, Kenneth Eng, Danielle Pancirer, Andrea Sboner, Rohan Bareja, Monica L. Guzman, Zohal Noorzad, Wayne Tam, Olivier Elemento, Shuhua Cheng, Palak Panchal, Gail J. Roboz, Sarah Nataraj, Duane C. Hassane, Himisha Beltran, Susan Mathew
Publikováno v:
NPJ Precision Oncology
npj Precision Oncology, Vol 5, Iss 1, Pp 1-10 (2021)
Sugita, Mayumi; Wilkes, David C; Bareja, Rohan; Eng, Kenneth W; Nataraj, Sarah; Jimenez-Flores, Reyna A; Yan, LunBiao; De Leon, Jeanne Pauline; Croyle, Jaclyn A; Kaner, Justin; Merugu, Swathi; Sharma, Sahil; MacDonald, Theresa Y; Noorzad, Zohal; Panchal, Palak; Pancirer, Danielle; Cheng, Shuhua; Xiang, Jenny Z; Olson, Luke; Van Besien, Koen; ... (2021). Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ precision oncology, 5(1), p. 44. Springer Nature 10.1038/s41698-021-00183-2
npj Precision Oncology, Vol 5, Iss 1, Pp 1-10 (2021)
Sugita, Mayumi; Wilkes, David C; Bareja, Rohan; Eng, Kenneth W; Nataraj, Sarah; Jimenez-Flores, Reyna A; Yan, LunBiao; De Leon, Jeanne Pauline; Croyle, Jaclyn A; Kaner, Justin; Merugu, Swathi; Sharma, Sahil; MacDonald, Theresa Y; Noorzad, Zohal; Panchal, Palak; Pancirer, Danielle; Cheng, Shuhua; Xiang, Jenny Z; Olson, Luke; Van Besien, Koen; ... (2021). Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. NPJ precision oncology, 5(1), p. 44. Springer Nature 10.1038/s41698-021-00183-2
The epichaperome is a new cancer target composed of hyperconnected networks of chaperome members that facilitate cell survival. Cancers with an altered chaperone configuration may be susceptible to epichaperome inhibitors. We developed a flow cytomet
Autor:
Robin Foà, Ahmet Dogan, Luca Vincenzo Cappelli, Steven M. Horwitz, Joseph Casano, Jude M Phillips, Paul Zumbo, Danilo Fiore, Liron Yoffe, David M. Weinstock, Leandro Cerchietti, Clarisse Kayembe, Federica Di Maggio, Elisa de Stanchina, Paola Ghione, Raul Rabadan, Zhaoqi Liu, Giorgio Inghirami, Wayne Tam, Inna Khodos, Shuhua Cheng, Doron Betel
Publikováno v:
Cancers
Volume 12
Issue 6
Cancers, Vol 12, Iss 1603, p 1603 (2020)
Volume 12
Issue 6
Cancers, Vol 12, Iss 1603, p 1603 (2020)
Breast implant-associated lymphoma (BIA-ALCL) has recently been recognized as an independent peripheral T-cell lymphoma (PTCL) entity. In this study, we generated the first BIA-ALCL patient-derived tumor xenograft (PDTX) model (IL89) and a matching c